This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D55.0 | V code: V163 | Synonyms: G6PD deficiency, Glucose-6-phosphate dehydrogenase deficiency, glucose-6-phosphate dehydrogenase deficiency anemia
The history of G6PD deficiency begins with cases of hemolytic anemia of unknown cause observed in US soldiers during World War II and the Korean War. In 1952, some researchers reported that rapid hemolysis occurred in certain soldiers given the antimalarial primaquine and first suggested that this phenomenon was due to a genetic predisposition of particular individuals. Then, in 1956, the Carson research team at the University of Chicago demonstrated, through a glutathione stability test of red blood cells, that glucose-6-phosphate dehydrogenase (G6PD) activity was markedly reduced in susceptible individuals. This discovery was a landmark study that first revealed an enzyme deficiency as the direct cause of a blood disorder, and it is recorded as a representative example of elucidating a disease mechanism from a biochemical phenotype in the era before molecular genetics developed.
Early research on G6PD deficiency focused mainly on drug- or infection-induced acute hemolytic episodes, but in the 1960s a special phenotype in which persistent chronic hemolytic anemia occurs even without any particular triggering factor, namely chronic nonspherocytic hemolytic anemia (CNSHA), began to be recognized as a separate clinical entity. In 1960, Valentine et al. described CNSHA occurring with the most severe G6PD variants, and the World Health Organization (WHO) subsequently classified G6PD variants into Classes I–V according to the degree of residual enzyme activity and clinical severity. Class I, in which enzyme activity remains below 10% of normal and CNSHA persists, is the most severe category and the practical target of rare disease registration. Since the 1970s, advances in molecular biology have elucidated how various gene variants are associated with the structural instability of the G6PD protein, and more than 200 variants have been reported to date.
In Korea, G6PD deficiency has mainly been discovered through neonatal jaundice screening or through hemolytic reactions after antimalarial administration during military service. G6PD gene variants in Korea show a somewhat different distribution from West Asian and Southeast Asian variants, and Korean-specific variants such as G6PD Seoul (c.1366A>T, p.Lys456Asn) have been reported. The Korea Rare Disease Foundation registers and manages Class I variants causing CNSHA as rare diseases, and sporadic domestic case reports have been published in Korean pediatric and clinical hematology journals. With the transition to a multicultural society, reports of diverse variants are also increasing, mainly in immigrant families from Southeast Asia.
G6PD is the first enzyme of the pentose phosphate pathway (PPP) and catalyzes the oxidation of glucose-6-phosphate (G6P) to 6-phosphogluconolactone. In this process, NADP+ is reduced to NADPH. NADPH provides the reducing power essential for regenerating reduced glutathione (GSH) from oxidized glutathione (GSSG) in red blood cells, and GSH is the key antioxidant molecule that protects hemoglobin and cell membrane proteins from reactive oxygen species (ROS) and oxidizing substances. Because mature red blood cells lack nuclei and mitochondria and can produce NADPH only through the pentose phosphate pathway, G6PD deficiency makes red blood cells specifically vulnerable to oxidative stress.
CNSHA occurs with Class I variants with extremely low enzyme activity. These variants severely impair the structural stability of the G6PD protein, so the enzyme is already rapidly degraded while red blood cells are being produced in the bone marrow, or the enzyme becomes completely nonfunctional in mature red blood cells. In this case, even without external oxidizing agents, red blood cell damage accumulates from endogenous ROS generated during normal oxygen transport alone, causing persistent hemolysis. Representative Class I variants include G6PD Harilaou, G6PD Nara, G6PD Beverly Hills, and G6PD Campinas, and in most, the variants are concentrated at the dimer or tetramer interface of the G6PD protein or at the NADP+ binding site.
G6PD Mahidol (c.487G>A, p.Gly163Ser), G6PD Canton (c.1376G>T, p.Arg459Leu), G6PD Kaiping (c.1388G>A, p.Arg463His), and others observed at high frequency in Southeast Asia mostly correspond to Class II–III and cause acute hemolysis triggered by precipitating factors rather than chronic hemolysis, but the Canton variant in particular sometimes shows a severe CNSHA phenotype comparable to Class I in some individuals. Reports of these variants are increasing among Southeast Asian migrant workers and marriage immigrants living in Korea, so caution is needed in newborn screening of multicultural families.
The G6PD gene is located on the long arm of the X chromosome (Xq28) and consists of 13 exons. The mode of inheritance is X-linked recessive, and in hemizygous males, the phenotype is fully expressed with only one variant allele. In females, clinical symptoms appear in homozygotes with variants on both alleles or in compound heterozygotes with two different variants, and heterozygous females show a spectrum ranging from normal to severe G6PD deficiency depending on the degree of X chromosome inactivation (lyonization). When lyonization is extremely skewed toward the variant X chromosome, heterozygous females can also experience a severe clinical course comparable to CNSHA.
The G6PD protein consists of 515 amino acids, and the active form is a homodimer or homotetramer. Most pathogenic variants are missense mutations, and nonsense variants and insertions/deletions are rare. Depending on the location of the variant, loss of enzyme function results from various mechanisms, including reduced protein stability, reduced substrate (G6P) binding affinity, damage to the NADP+ binding site, and damage to the dimer interface. In Class I CNSHA variants in particular, the variants are concentrated at residues critical for stabilizing the tertiary structure of the protein, so the enzyme tends to be degraded rapidly right after synthesis.
The WHO recommends newborn screening in regions with a high prevalence of G6PD deficiency. In Korea, G6PD testing is performed at some institutions as part of the newborn metabolic screening program, but national standardization has not yet been completed. For detection of female carriers, the fluorescent spot test alone is insufficient, and combined quantitative enzyme activity measurement and molecular genetic variant analysis are recommended. In particular, in patients suspected of CNSHA, carrier counseling through genetic analysis of family members is important.
G6PD deficiency is estimated to affect about 400–500 million people worldwide, which is the result of natural selection due to geographic overlap with malaria-endemic regions throughout human history. Women heterozygous and men hemizygous for G6PD deficiency are known to have some degree of resistance to infection with the malaria parasite (Plasmodium falciparum), and as a result, deficiency alleles have been maintained at high frequency in sub-Saharan Africa (prevalence 10–25%), Mediterranean countries, the Middle East, India, and Southeast Asia. The prevalence in Northeast Asia, including Korea, is relatively low at 0.1–1%, but with the transition to a multicultural society, patients with G6PD deficiency are gradually increasing in clinical practice.
Of all G6PD deficiency, Class I variants causing CNSHA are only a tiny minority, with only a few thousand cases reported worldwide. Class I variants are less frequent than other G6PD variants and are often found sporadically in independent small families. In Korea, G6PD deficiency with the CNSHA phenotype is extremely rare, with fewer than several dozen cases counted even in the national rare disease registry database. Manifest disease is far more common in males, but it can also occur in females with severely skewed lyonization or in the homozygous state.
CNSHA often presents as neonatal jaundice immediately after birth or anemia in infancy and is therefore mainly diagnosed in pediatrics. However, not a few individuals with mild Class I variants or some Class II variants live without particular symptoms until adulthood and are only diagnosed when they experience their first hemolytic episode after administration of certain drugs, eating certain foods (fava beans, fava bean), or acute infection.
In normal red blood cells, G6PD continuously produces NADPH through the pentose phosphate pathway, and this NADPH is used by glutathione reductase to regenerate GSH from GSSG. GSH directly neutralizes ROS and acts as a cofactor of glutathione peroxidase to reduce hydrogen peroxide (H2O2) to water. When G6PD is deficient, NADPH production decreases, causing GSH depletion, and accumulated ROS oxidize hemoglobin to form Heinz bodies. Red blood cells with Heinz bodies have reduced deformability, cannot pass through the splenic microcirculation, and are phagocytosed (extravascular hemolysis), and in severe cases, intravascular hemolysis with direct rupture of the red cell membrane also occurs.
In Class I variants, the structural instability of the G6PD protein itself is extremely severe, so the half-life of the enzyme in red blood cells is shortened to a few days to a few hours compared with normal (about 60 days). Therefore, from immediately after release from the bone marrow, red blood cells enter the circulation with almost no functional G6PD, cannot handle even the tiny amounts of ROS generated during endogenous oxygen transport, and a certain proportion of red blood cells is destroyed every day. Because this process continues even without external triggering factors, in CNSHA, unlike the acute episodic type, anemia is always present as a baseline state, and under stress, acute exacerbations are superimposed on the baseline hemolysis.
The body's compensatory responses to chronic hemolysis include increased bone marrow erythropoiesis (reticulocytosis), a right shift of the oxygen dissociation curve (decreased oxygen affinity of hemoglobin due to increased 2,3-DPG, assisting tissue oxygen delivery), and increased cardiac output. However, despite these compensatory mechanisms, chronic anemia at Hb levels of 7–10 g/dL persists in patients with Class I CNSHA, accompanied by progressive splenomegaly and gallstone (pigment stone) formation. In the long term, iron overload due to inefficient iron recycling from chronic hemolysis and excessive transfusion also emerges as a major complication.
G6PD deficiency with the CNSHA phenotype (Class I) can produce symptoms from immediately after birth. Neonatal jaundice is the most common initial symptom, and total bilirubin rising sharply within 24–72 hours after birth can reach levels requiring phototherapy or exchange transfusion. Later in infancy, persistent pallor, jaundice, and splenomegaly are observed, and growth and development may lag behind peers. Patients with severe Class I disease sometimes need transfusions within the first few months of life.
After childhood, general symptoms of chronic anemia such as chronic fatigue, exertional dyspnea, headache, and pallor persist. Cholecystitis and biliary obstruction symptoms due to the formation of pigment gallstones (bilirubin gallstones) in the gallbladder may appear from late childhood to adulthood. As splenomegaly progresses, patients may complain of left upper quadrant fullness and early satiety. On exposure to triggering factors (infection, drugs, fava beans), a rapid drop in hemoglobin is superimposed on the baseline chronic anemia (acute-on-chronic hemolysis), and symptoms of acute hemolytic anemia such as hematuria (hemoglobinuria), back pain, and extreme fatigue may appear.
The main physical signs observed in patients with CNSHA are as follows. Conjunctival pallor and scleral icterus due to chronic anemia are persistently observed, and in severe cases skin jaundice is also present. On abdominal examination, splenomegaly may be palpable beyond the left costal margin, and when the spleen becomes considerably enlarged from long-term hemolysis, abdominal distension is visible to the naked eye. When gallstone complications are present, right upper quadrant tenderness may be seen.
On peripheral blood smear, Heinz bodies (identified with special cresyl blue staining), bite cells (red blood cells bearing the traces of Heinz body removal in the spleen), spherocytes, and red cell fragments (schistocytes) may be observed. Typical laboratory findings are normocytic normochromic anemia, reticulocytosis, elevated serum indirect bilirubin, elevated serum lactate dehydrogenase (LDH), and decreased haptoglobin. The direct antiglobulin test (DAT, Coombs test) should be negative; if positive, differentiation from autoimmune hemolytic anemia (AIHA) is needed.
The fluorescent spot test is the WHO-recommended first-line screening method for G6PD deficiency, confirming the conversion of NADP+ to NADPH by the G6PD enzyme by the presence or absence of fluorescence. Blood is spotted on filter paper, G6P and NADP+ substrates are added, and the presence of NADPH fluorescence is observed under ultraviolet (UV) light. Blood from normal individuals shows bright fluorescence, while in G6PD-deficient individuals fluorescence is absent or markedly reduced. This test is simple to perform and inexpensive and can be used in resource-limited settings, but immediately after acute hemolysis, when reticulocytes are increased, it can give false negative results because young red blood cells have relatively high G6PD activity. Its sensitivity in heterozygous females is also low, so it is inappropriate for confirmation.
For newborn screening, quantitative measurement of G6PD activity using dried blood spots (DBS) is recommended. Recently, point-of-care portable fluorometric devices (such as CareStart G6PD) have been developed, making semiquantitative measurement of G6PD levels possible even in neonatal wards in resource-limited areas and in the field in malaria-endemic regions. These tools are particularly useful for perinatal screening in regions with a high risk of favism.
Quantitative measurement of red blood cell G6PD enzyme (spectrophotometric assay) is the standard for confirming G6PD deficiency. This test uses G6P substrate and NADP+ to measure the amount of NADPH produced per unit time as the change in absorbance at 340 nm, corrected for hemoglobin concentration and expressed in IU/g Hb. The normal reference for adult males is about 7–11 IU/g Hb, and Class I CNSHA variants often show enzyme activity below 10%. Because the proportion of young reticulocytes is high during or immediately after an acute hemolytic episode, normal values may be obtained, so retesting at steady state is important.
When G6PD deficiency is confirmed by enzyme activity measurement, the specific variant is identified and the Class determined by variant analysis of the G6PD gene (Xq28). Sanger sequencing, multiplex PCR-RFLP, and next-generation sequencing (NGS) panels are currently used, and for known variants, targeted variant detection (allele-specific PCR) is used for rapid diagnosis. Molecular diagnosis is essential particularly for detecting female carriers, confirming newborn screening results, and accurately classifying rare Class I variants.
Tests to be performed periodically for CNSHA evaluation include a complete blood count (CBC with reticulocyte count), peripheral blood smear, serum iron, ferritin, transferrin saturation, LDH, total/direct bilirubin, haptoglobin, and urine hemosiderin. Regular abdominal ultrasound to check spleen size and gallstones is also important for monitoring long-term complications.
The first measure to prevent acute exacerbations in patients with CNSHA is avoidance of known oxidative triggering factors. Checking G6PD status before prescribing oxidizing drugs (primaquine, dapsone, nitrofurantoin, methylene blue, high-dose ascorbic acid, etc.) is essential, and patients are educated to avoid eating fava beans (broad bean). Folic acid supplementation is recommended to replace folate consumed by excessive red cell production due to chronic hemolysis.
In severe CNSHA, red blood cell transfusion (packed red blood cells) is given when Hb is below 7 g/dL or clinical symptoms are severe. Iron overload due to repeated transfusions is a major long-term complication of Class I CNSHA, and regular monitoring of iron status using serum ferritin and liver MRI (T2* or R2*) is recommended. Iron chelators (deferoxamine, deferasirox, deferiprone) are introduced once iron overload is confirmed.
Splenectomy may be effective in improving hemoglobin levels and reducing transfusion frequency in transfusion-dependent CNSHA, but because the risk of sepsis due to encapsulated bacteria increases, pneumococcal, meningococcal, and Haemophilus vaccinations must be given first. In severe pediatric CNSHA, allogeneic hematopoietic stem cell transplantation (HSCT) may be considered as a curative treatment option, and when an HLA-matched donor is available, the patient can become free from long-term transfusion dependence and iron overload. Preclinical research on gene therapy is underway but has not yet reached the clinical stage.
The prognosis of patients with Class I CNSHA varies with the type of variant, the timing of diagnosis, and access to treatment. In settings where appropriate medical support is available, relatively normal daily life is possible through transfusions, folic acid supplementation, and avoidance of triggering factors. However, if iron overload from repeated transfusions is not managed, complications due to iron deposition in the heart, liver, and endocrine organs (heart failure, liver cirrhosis, diabetes, growth impairment) occur. Progression of splenomegaly may cause pancytopenia (hypersplenism), which may require surgical intervention.
The main causes of death in CNSHA include severe infection (including overwhelming sepsis after splenectomy), heart failure due to iron overload, and untreated acute-on-chronic hemolytic crises. Neurological damage due to neonatal kernicterus is an important sequela when not treated early. Overall, severe complications can be largely prevented through early diagnosis, education about triggering factors, and regular follow-up.
The most important measure in preventing G6PD deficiency is genetic counseling. In families that already have a patient with G6PD deficiency, the risk of occurrence in the next generation is assessed through parental testing and detection of carriers within the family. Prenatal diagnosis during pregnancy (fetal G6PD gene analysis by chorionic villus sampling or amniocentesis) is technically possible, but because G6PD deficiency is common and its phenotypic variability is large, clinical application of prenatal diagnosis is generally limited to families with the severe Class I phenotype.
Early detection of G6PD deficiency through newborn screening programs can prevent worsening of neonatal jaundice and kernicterus by avoiding administration of oxidizing drugs to the newborn and educating breastfeeding mothers to refrain from oxidizing foods (fava beans). Providing confirmed patients and caregivers with written materials, including lists of safe drugs and drugs to avoid, and continuously educating them to always disclose their G6PD deficiency when visiting medical institutions, is a key prevention strategy.